Reich Kristian 4
4 · MoonLake Immunotherapeutics · Filed Jul 21, 2026
Research Summary
AI-generated summary of this filing
MoonLake Immunotherapeutics (MLTX) Chief Scientific Officer Sells Shares
What Happened
Kristian Reich, Chief Scientific Officer of MoonLake Immunotherapeutics (MLTX), sold 43,700 ordinary shares on July 20, 2026. The shares were sold at a weighted-average price of $20.09 per share (range $20.00–$20.25), for total proceeds of approximately $877,933. The sales were executed pursuant to a Rule 10b5-1 trading plan adopted March 10, 2026.
Key Details
- Transaction date: July 20, 2026; Form 4 filed July 21, 2026 (within the standard two-business-day reporting window).
- Sale type / code: S (open-market sale executed under a 10b5-1 plan).
- Shares sold: 43,700; weighted-average price: $20.09; price range: $20.00–$20.25; proceeds ≈ $877,933.
- Shares owned after transaction: not disclosed in the provided filing excerpt.
- Footnotes of note:
- F1: Transaction executed under a Rule 10b5-1 trading plan (adopted 3/10/2026).
- F2: Reported price is a weighted average; shares sold in multiple transactions; issuer will provide per-price breakdown upon SEC staff request.
- F3: Some shares are owned by JeruCON Beratungsgesellschaft mbH; Dr. Reich may be deemed an indirect beneficial owner of those shares under Section 16.
Context
Sales made under pre-established 10b5-1 plans are generally treated as pre-planned transactions and are often routine; they do not, by themselves, prove current insider sentiment. This filing is a routine insider sale and was reported in a timely Form 4.
Insider Transaction Report
- Sale
Class A ordinary shares, par value $0.0001 per share
[F1][F2][F3]2026-07-20$20.09/sh−43,700$877,933→ 2,764,746 total(indirect: See footnote.)
- 35,389
Class A ordinary shares, par value $0.0001 per share
Footnotes (3)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026.
- [F2]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.25. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F3]Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.